NEW YORK, April 8, 2010 (GLOBE NEWSWIRE) -- The NASDAQ Stock Market® (Nasdaq:NDAQ) began trading today two new exchange-traded funds (ETFs) designed to provide leveraged and inverse exposure to the NASDAQ Biotechnology Index® (Nasdaq:NBI), the most widely used benchmark for U.S. biotechnology sector.1 The ETFs are sponsored by ProShares, the leading manager of leveraged and inverse ETFs.2
ProShares Ultra Nasdaq Biotechnology (Nasdaq:BIB) aims to provide investment results that correspond to 200% of the daily performance of the NASDAQ Biotechnology Index (before fees and expenses), while ProShares UltraShort Nasdaq Biotechnology (Nasdaq:BIS) seeks to produce 200% of the inverse daily performance of the NASDAQ Biotechnology Index (before fees and expenses).
These funds seek a 200% or -200% return of their indices for a single day before fees and expenses. Due to the compounding of daily returns, returns over periods other than one day will likely differ in amount and possibly direction from the target returns for the same period. Investors should monitor their holdings consistent with their strategies, as frequently as daily. The funds' prospectuses describing correlation, leverage and other risks are available at www.proshares.com.
"These new ProShares ETFs give investors additional flexibility to develop their trading strategies to their individual needs," said John Jacobs, Executive Vice President, NASDAQ OMX Global Index Group. "With the launch of these ETFs, investors can now employ new investment strategies involving some of the world's most innovative biotechnology companies."
The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. To view a list of companies in the index, visit https://indexes.nasdaqomx.com/weighting.aspx?IndexSymbol=NBI&menuIndex=0.
NASDAQ OMX is a global leader in creating and licensing strategy indexes and is home to the most widely watched indexes in the world. As a premier, full-service provider, the NASDAQ OMX Global Index Group is dedicated to designing powerful indexes that are in sync with a continually changing market environment. Utilizing its expanded coverage as a global company, NASDAQ OMX has approximately 1,400 diverse equity, commodity and fixed-income indexes in the U.S., Europe, and throughout the world.
NASDAQ OMX's calculation, licensing and marketing support provide the tools to measure and replicate global markets. The NASDAQ OMX Global Index Group's range of services covers the entire business process from index design to calculation and dissemination. For more information about NASDAQ OMX indexes, visit https://indexes.nasdaqomx.com/.
Access to essential historical index data for NASDAQ OMX indexes can be accessed from a single source, NASDAQ OMX Global Index Watch. For additional information, please visit https://indexes.nasdaqomx.com/indexwatch.aspx.
ProShares is part of ProFunds Group, the leader in leveraged and inverse funds.2 ProShares introduced the first leveraged and inverse ETFs in the U.S. in 2006. Since 1997, ProFunds mutual funds have provided investors with access to sophisticated investment strategies.
About NASDAQ OMX
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with approximately 3,700 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx).
NASDAQ Biotechnology Index® is a registered trademark of The NASDAQ OMX Group, Inc. (which with its affiliates and subsidiaries are collectively "NASDAQ OMX") and is licensed for use by ProShares. Neither the ProShares Ultra Nasdaq Biotechnology nor the ProShares UltraShort Nasdaq Biotechnology have been passed on by NASDAQ OMX as to their legality or suitability, and neither the ProShares Ultra Nasdaq Biotechnology nor the ProShares UltraShort Nasdaq Biotechnology is issued, endorsed or sold by NASDAQ OMX. NASDAQ OMX makes no warranties and bears no liability with respect to either the ProShares Ultra Nasdaq Biotechnology nor the ProShares UltraShort Nasdaq Biotechnology.
Cautionary Note Regarding Forward-Looking Statements
The matters described herein may contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about NASDAQ OMX's products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX's control. These factors include, but are not limited to, factors detailed in NASDAQ OMX's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
1Source: Bloomberg, based on average daily dollar volume of ETFs for the 12 months ended 3/31/2010.
2Source: Lipper, based on a worldwide analysis of all of the known providers of funds in these categories. The analysis covered ETFs, ETNs, and mutual funds by the number of funds and assets (as of 6/30/2009).
CONTACT: The NASDAQ OMX Group, Inc. Media Contact: Wayne Lee +1.301.978.4875 Wayne.D.Lee@NASDAQOMX.Com